Date: 2016-09-01
Type of information: Nomination
Compound:
Company: Vaximm (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 1, 2016, Vaximm announced the appointment of Matthias Schroff as Chief Executive Officer (CEO). Dr. Schroff has over fifteen years of experience in the biotechnology industry. Previously, he was CEO of Mologen, a publicly traded German biotech company, serving on the company’s executive board for over ten years. In the eight years that Dr. Schroff served as CEO, he built Mologen from an early preclinical stage to an established immuno-oncology company with programs in Phase 2 and 3 clinical trials.
- In addition to his position at Mologen, Dr. Schroff served on the Board of Directors of the biotech arm of the Association of Research-based Pharmaceutical Companies (vfA bio). He is the inventor of numerous patents in the field of immuno-oncology, RNAi and gene expression, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications. Dr. Schroff received his PhD in biochemistry from Freie Universität Berlin at the Institute of Molecular Biology and Biochemistry, where he was involved in clinical trials in immunotherapy against cancer as early as 1994.
Financial terms:
Latest news:
Is general: Yes
